Skip to main content

Coronavirus: Medical Treatments

Question for Department of Health and Social Care

UIN 47397, tabled on 5 September 2022

To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help evaluate future effectiveness of prophylactic covid-19 treatments.

This answer is the replacement for a previous holding answer.

Answered on

27 September 2022

RAPID C-19 has enabled active multi-agency oversight of national and international trial evidence for COVID-19 therapies for potential treatment and prophylactic indications. To date, evidence has strongly supported treatment use, although emerging evidence on prophylactic use is continuing to be reviewed.

We are monitoring a range of treatment products through the Protect-V study, including sotrovimab and niclosamide, as administered over a six-month period in vulnerable renal and immunosuppressed patients, to assess their effectiveness and suitability. Where material evidence is identified, the formation and implementation of United Kingdom-wide clinical access policies will follow as previously for other treatments.

Named day
Named day questions only occur in the House of Commons. The MP tabling the question specifies the date on which they should receive an answer. MPs may not table more than five named day questions on a single day.